Oncology-New York最新文献

筛选
英文 中文
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors. 遗传性肾肿瘤综合征与 mTOR 抑制剂的使用。
IF 1.8 4区 医学
Oncology-New York Pub Date : 2024-10-17 DOI: 10.46883/2024.25921027
José Luis Rodríguez-Olivares, Héctor Raúl González-Sánchez, Evelyn Lilian Beas-Lozano, Jazmin Arteaga-Vázquez, Elaine T Lam Md, María T Bourlon
{"title":"Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors.","authors":"José Luis Rodríguez-Olivares, Héctor Raúl González-Sánchez, Evelyn Lilian Beas-Lozano, Jazmin Arteaga-Vázquez, Elaine T Lam Md, María T Bourlon","doi":"10.46883/2024.25921027","DOIUrl":"10.46883/2024.25921027","url":null,"abstract":"<p><p>The Case A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%. A chest CT scan revealed pulmonary cystic lesions consistent with lymphangioleiomyomatosis and a right spontaneous pneumothorax, which resolved with the placement of a chest tube. Physical examination revealed a hypopigmented macule on the skin of the lumbar region, facial angiofibromas, and periungual fibromas. An abdominal MRI documented multiple bilateral renal tumors that were hypointense on T2-weighted imaging and showed a black boundary artifact, suggestive of fat-poor angiomyolipomas (AMLs). Subsequent percutaneous biopsy of the largest renal tumor confirmed the diagnosis of angiomyolipoma (positive for HMB-45 on immunohistochemistry). The brain MRI revealed subependymal nodules. The pulmonary function tests showed a mild obstructive pattern. Germline genetic testing confirmed the suspected diagnosis, and the patient started oral systemic treatment with everolimus (Afinitor) 10 mg once daily, along with dexamethasone rinses for prophylaxis.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care. 多学科团队会议:癌症护理中的实施障碍。
IF 1.8 4区 医学
Oncology-New York Pub Date : 2024-09-19 DOI: 10.46883/2024.25921026
Carl He
{"title":"Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care.","authors":"Carl He","doi":"10.46883/2024.25921026","DOIUrl":"10.46883/2024.25921026","url":null,"abstract":"<p><p>The multidisciplinary team meeting has become a fundamental component of cancer care across most of Europe, North America, and Australia. In certain institutions, it holds a mandatory role in the treatment planning of all patients with cancer. Although the multidisciplinary team meeting has demonstrated improved adherence to clinical protocols in the oncology field and serves as a valuable educational tool for clinicians, it is difficult to truly gauge its impact on clinical outcomes due to the wide heterogeneity in interinstitutional meeting practices and the varied data reporting clinical outcomes. This literature review will provide an overview of the history and contextual role of the multidisciplinary team meeting in cancer management and discuss the barriers to its implementation, offering means to navigate these barriers. This review will also explore the barriers to adherence to treatment recommendations offered by the multidisciplinary team meeting in cancer care, through the lens of the patient and health care provider.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia. 范式转变的导航 Venetoclax 治疗重新定义了急性髓性白血病的前景。
IF 1.8 4区 医学
Oncology-New York Pub Date : 2024-08-19 DOI: 10.46883/2024.25921025
Muhammad Hamza Gul, Aisha Rehman Siddiqui, Farwa Zehra, Malaika Rehmani, Faraz Waheed, Natasha Masood, Maleeha Saqib, Mahnoor Keen, Sharan Siddharth Keshetty, Maham Maqsood, Siddharth Arjun Atwal, Muhammad Hamza Sikandari, Abdul Baseer Wardak
{"title":"Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia.","authors":"Muhammad Hamza Gul, Aisha Rehman Siddiqui, Farwa Zehra, Malaika Rehmani, Faraz Waheed, Natasha Masood, Maleeha Saqib, Mahnoor Keen, Sharan Siddharth Keshetty, Maham Maqsood, Siddharth Arjun Atwal, Muhammad Hamza Sikandari, Abdul Baseer Wardak","doi":"10.46883/2024.25921025","DOIUrl":"10.46883/2024.25921025","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the accumulation of malignant myeloid progenitor hematopoietic cells in the bone marrow and peripheral blood. Recent studies have shown promising results with the use of small molecule inhibitors and targeted therapy in the treatment of patients with AML. One such molecule is venetoclax, which has been approved in AML by the FDA in combination with hypomethylating agents or low-dose cytarabine. We thoroughly searched electronic literature related to venetoclax and its role in AML, using databases such as MEDLINE, PubMed, Google Scholar, and PsychInfo, through April 2024. We applied population, intervention, comparison, and outcome criteria, specifically focusing on studies with a population using venetoclax from review articles and clinical trials. All selected studies were required to be in English, and any study that did not involve the use of venetoclax was excluded. A meticulous literature review was conducted to consolidate the current knowledge and new combination therapies on AML. In our review article, we focused on the latest advances in the treatment of patients with AML. Based on the literature, we recommend that physicians prioritize the use of venetoclax in the management of this deadly disease because it has been shown to significantly impact the course of the disease.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs. 新辅助卡培他滨加替莫唑胺治疗非典型肺NET
IF 1.8 4区 医学
Oncology-New York Pub Date : 2024-07-08 DOI: 10.46883/2024.25921024
Georgios Evangelou, Ioannis Vamvakaris, Irene Konstantopoulou, Konstantinos Syrigos
{"title":"Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs.","authors":"Georgios Evangelou, Ioannis Vamvakaris, Irene Konstantopoulou, Konstantinos Syrigos","doi":"10.46883/2024.25921024","DOIUrl":"10.46883/2024.25921024","url":null,"abstract":"<p><p>Neoadjuvant and adjuvant treatment in lung neuroendocrine tumors (NETs) is a field that has not been explored in-depth, with little information on the impact on disease-free survival. This case study highlights the effectiveness of neoadjuvant treatment with capecitabine plus temozolomide (CAPTEM) in a woman with well-differentiated atypical carcinoid. The patient was asymptomatic at diagnosis and was referred to the outpatient NET clinic at Sotiria Hospital in Athens, following an incidental finding on a chest x-ray. 18F-fluorodeoxyglucose (FDG) PET/CT and 68Ga-Dotatoc PET/CT revealed another mass in the pancreas, with avidity in both imaging studies. The patient underwent treatment for 6 months with CAPTEM with a response in the lung NET and mediastinal lymph nodes. However, the mass in the pancreas slightly increased and was removed with a central pancreatectomy. The patient continued treatment with CAPTEM for 6 more months. There was further response according to RECIST 1.1 criteria (partial response in the mediastinal lymph nodes and a 21% regression in the primary tumor size). Pathology report after lobectomy with lymph node dissection showed a pathologic complete response in the mediastinal lymph nodes. Twenty-four months after surgery, the patient remains disease-free and has a good quality of life. Although large clinical trials are needed, this case study underlines the value of preoperative chemotherapy in atypical carcinoids.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation. 一例罕见的 CDKN2A 基因突变转移性螺旋状腺癌病例
IF 1.8 4区 医学
Oncology-New York Pub Date : 2024-06-10 DOI: 10.46883/2024.25921022
Jonathan Q Trinh, Shristi Upadhyay Banskota, Alissa S Marr
{"title":"A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation.","authors":"Jonathan Q Trinh, Shristi Upadhyay Banskota, Alissa S Marr","doi":"10.46883/2024.25921022","DOIUrl":"10.46883/2024.25921022","url":null,"abstract":"<p><p>Spiradenocarcinomas are rare malignant skin adnexal tumors. We describe a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor. This case highlights the unique nature of spiradenocarcinomas as well as the potential benefit of targeted therapy.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141428261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials. 尽管试验结果呈阴性,Venetoclax 在 t(11;14) 多发性骨髓瘤中的应用依然成功。
IF 1.8 4区 医学
Oncology-New York Pub Date : 2024-06-10 DOI: 10.46883/2024.25921023
Zachary M Avigan, Joshua Richter Md
{"title":"Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.","authors":"Zachary M Avigan, Joshua Richter Md","doi":"10.46883/2024.25921023","DOIUrl":"10.46883/2024.25921023","url":null,"abstract":"<p><p>The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141428262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI Use in Prostate Cancer: Potential Improvements in Treatments and Patient Care. 人工智能在前列腺癌中的应用:治疗和患者护理的潜在改进。
IF 1.8 4区 医学
Oncology-New York Pub Date : 2024-05-13 DOI: 10.46883/2024.25921021
James B Yu Md Mhs Fastro, Julian C Hong
{"title":"AI Use in Prostate Cancer: Potential Improvements in Treatments and Patient Care.","authors":"James B Yu Md Mhs Fastro, Julian C Hong","doi":"10.46883/2024.25921021","DOIUrl":"10.46883/2024.25921021","url":null,"abstract":"<p><p>Artificial intelligence use in prostate cancer encompasses 4 main areas including diagnostic imaging, prediction of outcomes, histopathology, and treatment planning.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141082365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial. 哪种治疗方法适合哪种患者?PROSPECT 试验后的直肠癌管理。
IF 1.8 4区 医学
Oncology-New York Pub Date : 2024-05-13 DOI: 10.46883/2024.25921019
Seth Felder, Jessica Frakes, Manju George, Allison Rosen, Ibrahim Halil Sahin
{"title":"Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial.","authors":"Seth Felder, Jessica Frakes, Manju George, Allison Rosen, Ibrahim Halil Sahin","doi":"10.46883/2024.25921019","DOIUrl":"10.46883/2024.25921019","url":null,"abstract":"<p><p>Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141082467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From Endometriosis. 同步分化良好的乳头状间皮瘤和子宫内膜异位症引发的子宫内膜样腺癌
IF 1.8 4区 医学
Oncology-New York Pub Date : 2024-05-13 DOI: 10.46883/2024.25921020
Catherine R Lewis, Jocelyn Uchic-Boccella, Jenna Zimmerman, Eirwen Miller, Sharon Liang, Patrick L Wagner
{"title":"Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From Endometriosis.","authors":"Catherine R Lewis, Jocelyn Uchic-Boccella, Jenna Zimmerman, Eirwen Miller, Sharon Liang, Patrick L Wagner","doi":"10.46883/2024.25921020","DOIUrl":"10.46883/2024.25921020","url":null,"abstract":"<p><p>Well-differentiated papillary mesothelioma (WDPM) is a rare mesothelial tumor of uncertain malignant potential. We present a unique case of a woman with synchronous WDPM and well-differentiated endometrioid adenocarcinoma (EA) arising from extraovarian endometriosis. A 56-year-old postmenopausal woman presented with a several-month history of right lower quadrant abdominal pain. She had a history of supracervical hysterectomy and bilateral salpingo-oophorectomy secondary to endometriosis. Imaging reported a mass in the right lower quadrant originating from the distal ileum. At laparotomy, the patient underwent a right colectomy with resection of the terminal ileum and excision of a solitary peritoneal nodule. Pathology was consistent with a diagnosis of well-differentiated EA (arising from extraovarian endometriosis) and WDPM. Further treatment consisted of complete surgical staging/debulking and adjuvant chemotherapy directed toward metastatic well-differentiated EA. Surgeons should be familiar with WDPM as a potential finding in women of reproductive age undergoing abdominal surgery for any indication.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141082511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting. 在资源有限的环境中诊断和治疗痉挛性浆细胞树突状细胞肿瘤。
4区 医学
Oncology-New York Pub Date : 2024-03-01 DOI: 10.46883/2024.25921014
Fiza Khan, Foorquan Hashmi, Nerses Ghahramanyan, Elen Baloyan, Gevorg Tamamyan, Marina Konopleva, Naveen Pemmaraju, Astghik Voskanyan
{"title":"Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting.","authors":"Fiza Khan, Foorquan Hashmi, Nerses Ghahramanyan, Elen Baloyan, Gevorg Tamamyan, Marina Konopleva, Naveen Pemmaraju, Astghik Voskanyan","doi":"10.46883/2024.25921014","DOIUrl":"10.46883/2024.25921014","url":null,"abstract":"<p><p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options and poor prognosis. This case report presents the clinical course and management of a 62-year-old man with BPDCN in a resource-limited setting. The patient presented with constitutional symptoms and abnormal complete blood count findings. Initial treatment was performed with an acute lymphoblastic leukemia-based chemotherapy regimen, and the patient achieved complete remission, but the disease recurred 7 months after the initial diagnosis was confirmed in April 2022. The subsequent therapy was not effective, and the patient died during treatment. This case highlights the challenges in managing BPDCN and the need for further research to improve outcomes.</p>","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140186166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信